Background Previous studies have reported significant lower incidence yet greater risk of death from bladder cancer (BCa) in African-Americans compared with Caucasians. In this study, the overall survival amongst African-Americans and Caucasians with BCa within the state of Florida is evaluated. Materials and Methods The Florida Cancer Data System and the Florida Agency for Health Care Administration data sets were linked on the basis of unique identifiers, which identified 28,786 patients (27,811 Caucasian and 975 AfricanAmericans) with newly diagnosed BCa from January 1994-December 2009. Data in the database included race/ethnicity, age, smoking history, insurance status, treatment, tumor grade, tumor stage, and overall survival. Chi-square and MannWhitney U tests were used to compare variables between African-Americans and Caucasians. Survival rates were calculated by the Kaplan-Meier method while univariate effects were tested by the log-rank test, and multivariate effects were tested by Cox proportional-hazard regression model. P values less than 0.05 were considered statistically significant. Results Higher clinical stage bladder tumors including T3/4 disease (14.5 % vs. 8.0 %, p<0.001), lymph node involvement (7.3 % vs. 3.4 %, p<0.001), and metastatic disease (5.3 % vs. 1.7 %, p<0.001), as well as higher grade disease (60.2 % vs. 48 %, p<0.001) were more commonly reported in African-Americans than in Caucasians with newly diagnosed BCa. African-Americans tended to be treated with more aggressive therapies (e.g., radical cystectomy). After adjusting for all covariates, African-Americans actually had more favorable outcomes as related to overall survival (HR=0.35, 95 % CI, 0.12-0.98, p=0.045). Conclusions Though African-Americans initially present with more aggressive BCa, African-Americans actually have an improved overall survival compared with Caucasians. Though contrary to previous reports, our results may signify a more complex relationship between race and BCa outcomes and thus warrants further attention.
Introduction
Despite advances in cancer care, there is still a persistent disparity between the mortality rates of African-Americans and Caucasians with most types of cancers [1] . On average across all cancers, African-Americans have a 2.2-fold increase in developing cancer and a 20 % higher mortality rate from cancer compared with Caucasians [2] . These racial disparities related to the incidence of cancers and deaths from cancers are evident in some of the most common cancers affecting society (e.g., lung, prostate, breast, and colorectal cancers). For breast and colon cancers, it was found that African-Americans present with these cancers at a younger age and more advanced stage than Caucasians with these same cancers [3] . Furthermore, both breast and colon cancers in AfricanAmericans are associated with a reduction in 5-year diseasespecific survival compared with Caucasians (62.1 % vs. 70.4 % for breast cancer and 41.3 % vs. 45.4 % for colon cancer, respectively) [3] . Similarly with prostate cancer, the incidence is highest in African-Americans by nearly 50 % with a corresponding twofold increase in mortality rates amongst Africans-Americans compared with Caucasians. Moreover, African-Americans presented with higher-stage prostate cancer. However, when the data were corrected for socioeconomic factors as well as stage, being of AfricanAmerican descent still was associated with a reduction in 5-year survival [4] . Thus, in multivariate models, correcting for higher clinical stage and higher pathologic grade did not ameliorate this racial disparity related to survival. Additionally, this trend was seen in areas with high poverty rates and within equal access medical systems, thus illustrating that the racial disparity is not related to access to healthcare or quality of healthcare rendered [5] .
In the US, an estimated 74,690 new cases of bladder cancer (BCa) were diagnosed in 2014, and an estimated 15,580 patients died of this disease in the same year [1] . The incidence of BCa among Caucasians is higher compared with African-Americans. It is also well established that AfricanAmericans present with higher stage and higher-grade tumors at diagnosis [6] . Furthermore, African-Americans were noted to have a 70 % higher risk of cancer-related death compared with Caucasians [7] . Even when assessing survival among patients with localized disease, African-Americans possessed a significantly worse 10-year disease-specific survival compared with Caucasians [8] . In addition, results from a largescale epidemiologic study using the SEER database demonstrated that African-Americans diagnosed with early stage BCa have a 23 % higher risk of death from the disease than Caucasians [9] . Herein, we set out to study the presenting characteristics, therapy rendered, and overall survival among African-Americans with BCa within the state of Florida.
Materials and Methods

Study Population
The 2011 Florida Cancer Data System (FCDS) data set was used to identify all incident cases of bladder tumors diagnosed in the state of Florida. The FCDS data set was enhanced with 2007 data linked from the Florida Agency for Health Care Administration (AHCA) data set. AHCA maintains two databases (Hospital Patient Discharge Data and Ambulatory Outpatient Data) on all patient encounters within hospitals and freestanding ambulatory surgical and radiation therapy centers within Florida. All hospitals are required to report all discharges and outpatient encounters to AHCA since 1987. The AHCA data sets used in this study contain diagnoses and procedures performed during every hospitalization or outpatient encounter in the state of Florida, for the period 1994-2009. The comorbidity data obtained from the AHCA data set allowed for better correction of covariates. Tobacco data are self-reported at the time of cancer diagnosis, and information on duration of use was not available.
Cases in the FCDS and AHCA data sets were linked on the basis of unique identifiers. These matches were confirmed with the patient's date of birth and sex. Non-Florida residents were not included in the analysis. The staging criteria used by the FCDS are consistent with the Surveillance, Epidemiology, and End Results (SEER) summary staging [10] . In this study, local staging represents disease that does not extend beyond the primary organ, whereas those having positive lymph nodes at the time of resection were classified as having regional disease. Documentation of distant metastases during the perioperative period led to classification of affected patients as having distant disease.
Statistical Analysis
Correlations between variables were made using the Chisquare and Mann-Whitney U tests. Median overall survival rates were calculated by the Kaplan-Meier method. Because the FCDS collects only primary cause of death, we could only analyze overall survival and not disease-specific survival. Survival was calculated from the time of the initial diagnosis to date of last contact, or date of death, which was the time of censoring. The univariate effects of demographic, clinical, and tumor variables on survival were tested by the log-rank test for categorical values. To estimate the impact of race on survival outcomes, we used a Cox proportional hazards model, adding demographic, clinical, and treatment variables in a stepwise fashion. P values less than 0.05 were considered statistically significant. Statistical analysis was performed with SPSS Statistical Package version 15.0 (SPSS Inc., Chicago, IL).
Results
The characteristics of the study population are shown in Table 1 . The cohort included 27,811 (96.6 %) Caucasians and 975 (3.4 %) African-Americans. Among AfricanAmericans, one-third of the patients were females while, among Caucasians, one-fifth of the patients were female. Furthermore, the mean age for African-Americans with newly diagnosed BCa was 68 years compared with 72 years for Caucasians (p<0.0001). Caucasians were more likely than African-Americans to have a history of tobacco use and to be on government insurance (Medicare or Medicaid). The most common histologic subtype of cancer was transitional cell carcinoma (TCC) present in >92 % of the AfricanAmericans and Caucasian patients; however, other histologic subtypes (e.g., squamous cell carcinoma, adenocarcinoma) were more common amongst African-Americans than Caucasians (7.9 % vs. 3.1 %, p < 0.0001). Moreover, African-Americans presented with higher stage and highergrade tumors. For example, more African-Americans presented with clinical T3/4 disease than Caucasians (14.5 % vs. 8 %, p<0.0001), more African-Americans presented with node positive disease than Caucasians (7.3 % vs. 3.4 %, p<0.0001), and more African-Americans presented with metastatic disease than Caucasians (5.3 % vs. 1.7 %, p<0.0001). In addition, more African-Americans presented with high grade tumors (G3) than Caucasians (60 % vs. 48 %, p<0.0001). Since African-Americans presented with more adverse disease characteristics (e.g., high grade and high stage), it is not surprising then that the percentage of African-Americans undergoing curative surgery (e.g., cystectomy or pelvic exenteration), systemic therapy, or definitive radiation therapy was significantly greater than the percentage of Caucasians undergoing these therapies (Fig. 1) . In order to further elucidate whether AfricanAmericans received more aggressive therapy, we analyzed treatments received stratified by stage of the disease and identified that more African-Americans with Ta and T1 underwent cystectomy/pelvic exenteration compared to Caucasians. However, more Caucasians underwent cystectomy/pelvic exenteration for Tis, T2, or T4 disease (Supplemental Table 1 ). Figure 2 , a and b, show the Kaplan-Meier plots for overall survival rates among African-Americans and Caucasians based on clinical stage, tumor grade, and histological subtypes. The difference in the univariate log-rank analysis in the overall survival curves among Caucasians and AfricanAmericans was not statistically significant (p=0.15). The median overall survival rates for African-Americans and Caucasians were (16 months vs. 11 months, respectively, p<0.001). Table 2 shows the univariate and multivariate (adjusted simultaneously for all study variables) hazard ratios (HRs) for associations between demographic, clinical factors, tumor stage, and grade with overall survival. The highest HR in the multivariate analysis (HR=4.81; 95 % CI=2.49 to 9.3, p<0.001) was for metastatic disease compared with nonmetastatic disease. Female gender, higher stage, higher grade, and current tobacco use were also statistically significant variables conveying a poor prognosis (i.e., reduced OS). Interestingly, public insurance and being of AfricanAmerican descent were statistically significant variables conveying a favorable prognosis (i.e., improved overall survival).
Discussion
Based on comparative data from the National Cancer Institute, Africans-Americans possess nearly half the likelihood of developing BCa (incidence rate 11.0 per 100,000 cases for Africans-Americans and 21.7 per 100,000 cases for Caucasians) [2] , which shifts the burden of the disparity to Caucasians who possess the higher incidence of BCa. Interestingly, despite the dramatically lower incidence of BCa amongst Africans-Americans, Africans-Americans have been reported to have a 23 % increased in mortality from BCa, thus an incongruence of mortality rate and incidence rate is observed that is not observed in other cancers [2, 11] .
A SEER study showed that, in addition to higher mortality rates, Africans-Americans are also more likely to present with higher-grade bladder tumor than Caucasians as well as present with higher-stage bladder tumor than Caucasians [12] . This predilection for higher-stage and higher-grade disease at diagnosis was consistent with our results. In addition, these patients with more aggressive disease were more likely to receive curative surgery [13] , which, again, was consistent with our data. Furthermore, Africans-Americans were more likely than Caucasians to have histologic subtypes other than transitional cell carcinoma of the bladder including adenocarcinoma and squamous cell carcinoma [2, [14] [15] [16] , confirmed in our current study. However, while controlling for these factors, we could not demonstrate a reduction in overall survival, while other investigators documented the reduction in overall survival. This may be explained by several factors. First, we noted a higher incidence of tobacco use amongst our Caucasian patients (35.2 % of Caucasians vs. 23.2 % of African-Americans), which could translate into higher mortality rates. Furthermore, we had slightly higher percentage of African-Americans in our study compared with the study by Hollenbeck et al. [9] (3.4 % vs. 2.3 %). Though still a small population, our larger African American cohort may be able to fully unveil survival differences not observed in studies with small African-American populations. Thirdly, the current report encompassed different study dates 1994-2009 vs. 1992-2002 reported by Hollenbeck [9] . These slight differences in dates may factor in evolution of therapeutic management of the patient with BCa (e.g., institution of neoadjuvant chemotherapy) and thus may affect the reported survival. [17] . The difference in the number of patients and the dates accessed could account for any differences in results. Lastly, the availability of critical confounding data (e.g., limited access to healthcare or difference in tumor biology) could not be accounted for in the current study. We are now in the process of analyzing a large bladder cancer cohort from the VA system to determine if access to healthcare services plays a role the presentation and outcomes of various racial groups. Furthermore, based on our previous molecular profiling of bladder tumors [18, 19] , we are determining if AfricanAmericans and Caucasians with BCa, matched for clininopathologic features, have different molecular signatures and thus begin to hint at different tumor biology. Though a large study, limitations are present in this current study. First, these retrospective databases were not allinclusive and lacked critical information such as tumor recurrence and disease-specific survival. In particular, a large percentage of patients with T2 disease was not reported to have undergone the most common practice pattern for T2 disease in the US, radical cystectomy. In addition, racial identification was via self-reporting, which has its drawbacks and can introduce bias [20, 21] . Furthermore, though larger than previous studies, African-Americans still comprised an extremely small proportion of our study group. Thirdly, the population dynamics of the study were limited to one geographic location, and this may not reflect the population statistics of the US. In the current study, we continue to add to the body of literature that reports that (a) African-Americans present with higher-stage and higher-grade BCa and (b) AfricanAmericans present with more non-transitional cell carcinoma histologic subtypes of BCa. However, we could not validate after adjusting for important covariates such as age, tumor stage, tumor grade, treatment rendered, health insurance, and tobacco history that there is a reduction in overall survival in African-Americans with BCa compared with Caucasians with BCa. Though contrary to previous reports, our results may signify a more complex relationship between race and BCa outcomes and thus warrants further attention. 
